As they move corporate resources from sales to R&D and attempt to adapt to new business dynamics, pharma and biotech companies must become far smarter in building the case for coverage and reimbursement. Increasingly, drug makers are understanding the need to build the case early in drug discovery and development, demonstrate the value proposition, and effectively communicate – or even partner – with payors (health plans, drug plans, PBMs) and purchasers (Medicare, Medicaid, employers).
To learn more, please listen to Mark Senak’s latest podcast. In it, I briefly explain the need to build value-driven, payor-friendly cases for drug coverage and reimbursement and to do so early.
Eye on FDA is Mark Senak’s popular blog on drug industry regulation, the FDA, and strategic communications strategies. In addition to providing thoughtful analyses and useful resources in his blog, Mark also podcasts interviews with industry executives, FDA officials, and top thought leaders.